310 related articles for article (PubMed ID: 20686448)
1. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL
Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
3. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
4. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.
Ravichandran K; Zafar I; He Z; Doctor RB; Moldovan R; Mullick AE; Edelstein CL
Hum Mol Genet; 2014 Sep; 23(18):4919-31. PubMed ID: 24847003
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
6. Ablation of Long Noncoding RNA Hoxb3os Exacerbates Cystogenesis in Mouse Polycystic Kidney Disease.
Weisser I; Eckberg K; D'Amico S; Buttram D; Aboudehen K
J Am Soc Nephrol; 2024 Jan; 35(1):41-55. PubMed ID: 37953472
[TBL] [Abstract][Full Text] [Related]
7. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus reduces polycystic liver volume in ADPKD patients.
Qian Q; Du H; King BF; Kumar S; Dean PG; Cosio FG; Torres VE
J Am Soc Nephrol; 2008 Mar; 19(3):631-8. PubMed ID: 18199797
[TBL] [Abstract][Full Text] [Related]
9. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
Serra AL; Poster D; Kistler AD; Krauer F; Raina S; Young J; Rentsch KM; Spanaus KS; Senn O; Kristanto P; Scheffel H; Weishaupt D; Wüthrich RP
N Engl J Med; 2010 Aug; 363(9):820-9. PubMed ID: 20581391
[TBL] [Abstract][Full Text] [Related]
11. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
[TBL] [Abstract][Full Text] [Related]
12. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.
Leonhard WN; van der Wal A; Novalic Z; Kunnen SJ; Gansevoort RT; Breuning MH; de Heer E; Peters DJ
Am J Physiol Renal Physiol; 2011 May; 300(5):F1193-202. PubMed ID: 21345977
[TBL] [Abstract][Full Text] [Related]
13. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus.
Stayner C; Shields J; Slobbe L; Shillingford JM; Weimbs T; Eccles MR
Nephrology (Carlton); 2012 Nov; 17(8):739-47. PubMed ID: 22725947
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in patients with autosomal dominant polycystic kidney disease.
Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
Tao Y; Kim J; Schrier RW; Edelstein CL
J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
[TBL] [Abstract][Full Text] [Related]
17. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease.
Kipp KR; Rezaei M; Lin L; Dewey EC; Weimbs T
Am J Physiol Renal Physiol; 2016 Apr; 310(8):F726-F731. PubMed ID: 26764208
[TBL] [Abstract][Full Text] [Related]
18. mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease.
Belibi F; Ravichandran K; Zafar I; He Z; Edelstein CL
Am J Physiol Renal Physiol; 2011 Jan; 300(1):F236-44. PubMed ID: 20943770
[TBL] [Abstract][Full Text] [Related]
19. Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2.
Ravichandran K; Ozkok A; Wang Q; Mullick AE; Edelstein CL
Am J Physiol Renal Physiol; 2015 Feb; 308(4):F349-57. PubMed ID: 25537744
[TBL] [Abstract][Full Text] [Related]
20. [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option].
Serra AL; Wüthrich RP
Praxis (Bern 1994); 2009 Dec; 98(25):1511-6. PubMed ID: 20013687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]